ABSTRACT
Objective To evaluate the effect of aromatherapy on chemotherapy-induced nausea and vomiting among lung cancer. Methods A total of 112 patient with lung cancer from Tianjin Cancer Hospital were selected and divided into control group(54 patients)and intervention group(58 patients)by random number table.The control group was given routine health care,while the intervention group was given aromatherapy and routine health care. Chinese Version of Gastroenteric Nausea and Vomiting Grading Criteria was adopted to assess chemotherapy-induced nausea and vomiting among before chemotherapy, 48 h and 5 to 7 days after chemotherapy. Functional Living Index-Emesis was used to measure quality of life among the first day, the sixth day and the eleventh day after chemotherapy. Results The study showed that there were statistical differences between two groups for acute nausea in the first(Z=-3.000, P=0.003) and third cycles (Z=-2.547, P=0.011), while there were no statistical differences in second(Z=-0.715, P=0.474) and fourth cycles (Z=-1.576, P=0.117). And for acute vomiting,all cycles had statistical significance(Z=-2.031,-2.291,-3.499,P=0.042,0.022,0.001)except the first cycle(Z=-2.830,P=0.777).There were differences among four cycles about delayed nausea and vomiting(Z=-3.475--2.144, P=0.001-0.032). It had statistical significance between control group and intervention group for quality of life(t=0.317-3.760,P=0.000-0.038). Conclusions Aromatherapy can obviously reduce extent of chemotherapy-induced nausea and vomiting, improve quality of life, so it is worth using widely in clinic.
ABSTRACT
In recent years, the number of advanced non-small cell lung cancer (NSCLC) patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to targeted therapy epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) or chemotherapy. The clinical treatment effect is also not satisfactory. Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit. ALTER0303 trail, phase III study has demonstrated that Anlotinib significantly prolonged overall survival (OS) and progression-free survival (PFS) in advanced NSCLC patients as 3rd line treatment.Here we report a case of advanced lung adenocarcinoma harboring KRAS mutation treated with Anlotinib. .
Subject(s)
Aged , Humans , Male , Adenocarcinoma , Drug Therapy , Genetics , Pathology , Adenocarcinoma of Lung , Antineoplastic Agents , Therapeutic Uses , Indoles , Therapeutic Uses , Lung Neoplasms , Drug Therapy , Genetics , Pathology , Mutation , Proto-Oncogene Proteins p21(ras) , Genetics , Metabolism , Quinolines , Therapeutic UsesABSTRACT
Objective To evaluate the value of IgA and IgG antibodies against α-fodrin in both serum antibodies in SS is also assessed.Methods Samples from 39 patients with SS(25 primary and 14 secondary),8 patients with systemic lupus erythematosus(SLE),and 15 patients with rheumatoid arthritis (RA)as well as 10 healthy blood donors were collected.Anti-α-fodrin antibodies were measured using ELISA.Results The titer of serum anti-α-fodrin was higher in SS than in other connective tissue diseases group and healthy group(P<0.01).IgA type anti-α-fodrin antibodies was detected in 60%.44% of serum and saliva in patients with pSS respectively.IgG antibodies were detected in 43% of sera,and 29% of saliva of patients with pSS.The sensitivity and specificity of serum anti-α-fodrin IgA in SS was 54%and 85%.The level of anti-α-fodrin was positively associated with xerostomia and parotid swelling (P<0.05),and was negatively associated with xeroma,renal tubule acidosis,lung interstitial disease and hepatic damages(P>0.05).Conclusion Saliva and serLlm anti-α-fodrin level may be diagnostic for SS.It may be a useful screening marker.